PLRP-S Polymeric Reversed-Phase Column for LC/MS Separation of mabs and ADC

Similar documents
Analysis of Monoclonal Antibody (mab) Using Agilent 1290 Infinity LC System Coupled to Agilent 6530 Accurate-Mass Quadrupole Time-of-Flight (Q-TOF)

Precise Characterization of Intact Monoclonal Antibodies by the Agilent 6545XT AdvanceBio LC/Q-TOF

Reproducible LC/MS Peptide Separation Using Agilent AdvanceBio Peptide Plus Columns

Application of Agilent AdvanceBio Desalting-RP Cartridges for LC/MS Analysis of mabs A One- and Two-dimensional LC/MS Study

Fast and Efficient Peptide Mapping of a Monoclonal Antibody (mab): UHPLC Performance with Superficially Porous Particles

Profiling Glycosylation of Monoclonal Antibodies at Three Levels Using the Agilent 6545XT AdvanceBio LC/Q TOF

Clone Selection Using the Agilent 1290 Infinity Online 2D-LC/MS Solution

Separation of Native Monoclonal Antibodies and Identification of Charge Variants:

Characterize mab Charge Variants by Cation-Exchange Chromatography

Peptide Mapping of Glycoprotein Erythropoietin by HILIC LC/MS and RP-LC/MS

Characterize Fab and Fc Fragments by Cation-Exchange Chromatography

Characterization of Glycosylation in the Fc Region of Therapeutic Recombinant Monoclonal Antibody

Critical Quality Attribute Assessment by Peptide Mapping Using LC/MS with Superficially Porous Columns

Put the PRO in Protein Characterization

CQA Assessment by Peptide Mapping Using LC/MS with an AdvanceBio Peptide Plus Column

MAbPac RP Column. High-performance reverse phase chromatography column for monoclonal antibody analysis

Application Note. Author. Abstract. Biotherapeutics and Biologics. Sonja Schneider Agilent Technologies, Inc. Waldbronn, Germany

Development of Analysis Methods for Therapeutic Monoclonal Antibodies Using Innovative Superficially Porous Particle Biocolumns

N-Glycan Profiling Analysis of a Monoclonal Antibody Using UHPLC/FLD/Q-TOF

Analysis of Nucleosides Using an Agilent Infinity II High Speed UHPLC with the 6130 Single Quadrupole Mass Selective Detector

Monoclonal Antibody Analysis on a Reversed-Phase C4 Polymer Monolith Column

Analysis of Monoclonal Antibodies and Their Fragments by Size Exclusion Chromatography Coupled with an Orbitrap Mass Spectrometer

Application Note. Authors. Abstract. Ravindra Gudihal Agilent Technologies India Pvt. Ltd. Bangalore, India

Rapid UHPLC Analysis of Reduced Monoclonal Antibodies using an Agilent ZORBAX Rapid Resolution High Definition (RRHD) 300SB-C8 Column

Quantification of Host Cell Protein Impurities Using the Agilent 1290 Infinity II LC Coupled with the 6495B Triple Quadrupole LC/MS System

4/4/2013. BioHPLC columns. Paul Dinsmoor Biocolumn Technical Specialist. April 23-25, Size Exclusion BioHPLC Columns

ADVANCE ACCURACY AND PRODUCTIVITY FOR FASTER ANALYSIS

Cell Clone Selection Using the Agilent Bio-Monolith Protein A Column and LC/MS

Fast and High-Resolution Reversed-Phase Separation of Synthetic Oligonucleotides

BioHPLC columns. Tim Rice Biocolumn Technical Specialist

Application Note. Abstract. Author. Biopharmaceutical

Peptide Mapping: A Quality by Design (QbD) Approach

A Comprehensive Approach for Monoclonal Antibody N-linked Glycan Analysis from Sample Preparation to Data Analysis

Ensure your Success with Agilent s Biopharma Workflows

Disulfide Linkage Analysis of IgG1 using an Agilent 1260 Infinity Bio inert LC System with an Agilent ZORBAX RRHD Diphenyl sub 2 µm Column

Size Exclusion Chromatography/ Mass Spectrometry Analysis of Antibody Drug Conjugates Using the Agilent 1260 Infinity II Bio-Inert LC

Cell Culture Optimization Using an Agilent Bio-Monolith Protein A Column and LC/MS

Application Note. Biopharma. Authors. Abstract. James Martosella, Phu Duong Agilent Technologies, Inc Centreville Rd Wilmington, DE 19808

An Integrated Workflow for Intact and Subunits of Monoclonal Antibody Accurate Mass Measurements

Biotherapeutic Method Development Guide

Biotherapeutic Method Development Guide

Intact & Subunit Purity

Columns for Biomolecules BioLC Column Lines

Host Cell Protein Analysis Using Agilent AssayMAP Bravo and 6545XT AdvanceBio LC/Q-TOF

mabs and ADCs analysis by RP

Enabling routine characterization of proteins. Agilent MassHunter BioConfirm software

Antibody Analysis by ESI-TOF LC/MS

Solutions for the Core and Protein Laboratory: MassHunter Walkup

ADVANCE ACCURACY AND PRODUCTIVITY FOR FASTER ANALYSIS

A streamlined drug-to-antibody ratio determination workflow for intact and deglycosylated antibody-drug conjugates

Reversed-phase Separation of Intact Monoclonal Antibodies Using Agilent ZORBAX Rapid Resolution High Definition 300SB-C8 1.

AdvanceBio Peptide Mapping

Answers, Simple and Streamlined. Solutions for Biotherapeutic Intact Mass Analysis

LC/MS Based Quantitation of Intact Proteins for Bioanalytical Applications

Benefits of 2D-LC/MS/MS in Pharmaceutical Bioanalytics

Isotopic Resolution of Chromatographically Separated IdeS Subunits Using the X500B QTOF System

Peptide Mapping. Hardware and Column Optimization

Chromatographic Workflows for Biopharmaceutical Characterization

Analysis of Monoclonal Antibody N-glycans by Fluorescence Detection and Robust Mass Selective Detection Using the Agilent LC/MSD XT

Identifying Monoclonal Antibody Mutation Sites Using the Agilent 1290 Infinity II 2D-LC Solution with Q-TOF LC/MS

Fraction Analysis of Cysteine Linked Antibody-Drug Conjugates Using Hydrophobic Interaction. chromatography. Agilent 1260 Infinity II Bio-Inert System

Analysis of Intact and C-terminal Digested IgG1 on an Agilent Bio MAb 5 µm Column

Highly Confident Peptide Mapping of Protein Digests Using Agilent LC/Q TOFs

Analysis of Intact Monoclonal Antibodies Using an M3 MicroLC with the TripleTOF 6600

A Complete Workflow Solution for Intact Monoclonal Antibody Characterization Using a New High-Performance Benchtop Quadrupole- Orbitrap LC-MS/MS

Charge Heterogeneity Analysis of Rituximab Innovator and Biosimilar mabs

Advanced Characterization of Antibody Drug Conjugates (ADCs) by Liquid Chromatography and Mass Spectrometry (LC/MS) John Gebler, Ph.D.

Application Note. Authors. Abstract. Ravindra Gudihal Agilent Technologies India Pvt. Ltd. Bangalore India

Monoclonal Antibody Charge Variants Identification by Fully Automated Capillary Isoelectric Focusing Mass Spectrometry

Agilent AdvanceBio SEC Columns for Aggregate Analysis: Instrument Compatibility

Analysis of Monoclonal Antibodies and Their Fragments by Size-Exclusion Chromatography Coupled with an Orbitrap Mass Spectrometer

mab and ADC Analysis Shanhua Lin, Ph.D. The world leader in serving science

Biotherapeutic Non-Reduced Peptide Mapping

AdvanceBio HIC: a Hydrophobic HPLC Column for Monoclonal Antibody (mab) Variant Analysis

Rapidly Characterize Antibody- Drug Conjugates and Derive Drug-to-Antibody Ratios Using LC/MS

ADVANCING ATTRIBUTE CONTROL OF ANTIBODIES AND ITS DERIVATIVES USING HIGH RESOLUTION ANALYTICS

Simple, Robust, High Quality Intact Mass Analysis A Biosimilars Case Study

Application Note # ET-20 BioPharma Compass: A fully Automated Solution for Characterization and QC of Intact and Digested Proteins

High-throughput and Sensitive Size Exclusion Chromatography (SEC) of Biologics Using Agilent AdvanceBio SEC Columns

Fast Online Desalting of mabs Using a Reversed-Phase Desalting Cartridge for LC-MS Analysis

Characterizing Antibody-Drug Conjugates Using Micro Pillar Array Columns Combined with Mass Spectrometry (µpac -MS)

Separation of Recombinant Human Erythropoietin (repo) Using Agilent Bio SEC-3

A comprehensive CE/ESI-MS solution for BioPharma applications

Robustness of the Agilent Ultivo Triple Quadrupole LC/MS for Routine Analysis in Food Safety

Reducing Cycle Time for Charge Variant Analysis of Monoclonal Antibodies

Fast and High Resolution Analysis of Intact and Reduced Therapeutic Monoclonal Antibodies (mabs)

Application Note. Abstract. Authors. Introduction. Environmental

The clearly better choice

Developing Quantitative UPLC Assays with UV

Application Note. Author. Introduction. Ravindra Gudihal Agilent Technologies India Pvt Ltd

Monitoring of Mammalian Cell Culture Media with HILIC LC/MS

Separate and Quantify Rituximab Aggregates and Fragments with High-Resolution SEC

Thermo Scientific MAbPac HIC Columns. Novel Hydrophobic Interaction HPLC Columns. Designed for Monoclonal Antibody Analysis

Biochromatography Bring more Zen into your life and laboratory

NISTmAb characterization with a high-performance RP chromatography column

Characterization of intact monoclonal antibody with microfluidic chip electrophoresis mass spectrometry

Clearly better LC/MS solutions

Agilent BioHPLC Columns PROTEIN IDENTIFICATION AND IMPURITY PROFILING USING REVERSED-PHASE HPLC/UHPLC

Quantification of genotoxic "Impurity D" in Atenolol by LC/ESI/MS/MS with Agilent 1200 Series RRLC and 6410B Triple Quadrupole LC/MS

Improved Peptide Maps Using Core-Shell Media: Explaining Better Biopharmaceutical Applications With Kinetex C18 Columns

Transcription:

PLRP-S Polymeric Reversed-Phase Column for LC/MS Separation of mabs and ADC Analysis of Intact and Fragmented mabs and ADC Application Note Biotherapeutics and Biologics Author Suresh Babu C.V. Agilent Technologies, Inc. Abstract This application note describes the application of polymeric-based reversed phase columns for the characterization of large biomolecules such as monoclonal antibodies (mabs) and antibody drug conjugate (ADC). Studies of both intact and fragment levels of mabs were carried out to understand the performance of the polymeric column. The results demonstrate the superior separation performance of the column, and its suitability for routine LC/MS analysis of mabs and ADC. Introduction Monoclonal antibodies (mabs) and antibody drug conjugates (ADCs) are therapeutic molecules that are heterogeneous in nature []. These molecules can undergo various modifications during the drug development process requiring thorough characterization to ensure safety and efficacy. Reversed-phase liquid chromatography with mass spectrometry detection is most commonly used for primary characterization of mabs and ADCs. The correct choice of LC column and method is critical to achieve reproducible high-resolution separations and high quality MS data. Typically, using formic acid (FA), an MS-friendly ion-pairing agent, in the mobile phase leads to poor total ion chromatogram (TIC) peak shape with traditional silica based reversed-phase columns. This affects LC/MS results (resolution, sensitivity, MS signal, accurate molecular weight information, and so forth). Hence, there is a critical requirement for an LC column compatible with formic acid conditions for enhanced LC/MS analysis of biomolecules.

This study used a polymeric reversed-phase column (Agilent PLRP-S) to demonstrate the LC/MS analysis of mabs and ADC. PLRP-S columns contain rigid, macroporous, spherical particles of polystyrene and divinylbenzene. They are physically and chemically stable across the complete ph range. The particles are inherently hydrophobic, therefore, neither bonded phases nor alkyl ligands are required for reversed-phase separations. This gives a highly reproducible material that is free from silanols and heavy metal ions. In this work, multiple therapeutic mabs, including ADC, were analyzed using the PLRP-S column in an LC/MS method. This approach delivered better LC/MS results, and accurate mass determination of intact and fragmented mabs and ADC. Materials and methods Samples Therapeutic mab, mab, and ADC (lysine-conjugated) were purchased from a local pharmacy, and stored according to the manufacturer s instructions. Intact: mab, mab, and ADC were diluted to a concentration of µg/µl using.% formic acid in % acetonitrile (ACN), and µl was injected. Reduction: μl of mab ( μg/µl) sample was mixed with μl dithiothreitol (DTT) ( M) followed by incubation at 7 C for hour. Papain digestion: μl of mab ( μg/μl) sample was mixed with μl digestion buffer (with cysteine), μl of activated papain (Sigma). The mixture was incubated at 7 C for hours. IdeS proteolytic digestion: μl of mab ( μg/μl) sample was mixed with. μl FabRICATOR ( Units) (Sigma) and the mixture was incubated at 7 C for hour. Conditions Agilent 9 Infinity LC system Column: Agilent PLRP-S,. mm, µm,,å (p/n PL 9-) Injection volume: µl Sample thermostat: C Mobile phase A: Mobile phase B:.% FA in water.% FA in ACN Gradient: Intact Fragments Stop time: Post time: at min % B at min % B at min % B at min 7% B at min 9% B at. min % B. min min Column temperature: 8 C Flow rate:. ml/min Agilent Accurate-Mass Q-TOF LC/MS Ion mode: Drying gas temperature: C Drying gas flow: at min % B at min % B at. min 8% B at min 8% B at. min % B Positive ion mode, dual AJS ESI (profile) 8 L/min Sheath gas temperature: C Sheath gas flow: Nebulizer: Capillary voltage: Fragmentor voltage: Skimmer voltage: Oct RF Vpp: Acquisition parameters MS mode: L/min psi, V 8 V V 7 V Data acquired at GHz, MS only mode, mass range -, m/z (fragments),,, m/z (intact) Instrumentation LC: Agilent 9 Infinity LC system MS: Agilent Accurate-Mass Quadrupole Time of Flight (Q-TOF) with an Agilent Jet Stream ion source

Results and Discussion To achieve better chromatographic performance, trifluoroacetic acid (TFA) is typically added to the mobile phase as an ion-pairing agent to provide sharper chromatographic peaks. However, TFA is not suitable for MS analysis due to its signal suppression effect []. Formic acid is the preferred MS-friendly ion-pairing agent for biomolecule applications, but can cause poor peak shape on traditional silica-based columns. Achieving good chromatographic peak shape and a high signal-to-noise ratio (S/N) m/z mass spectrum is a tradeoff when working with high molecular weight proteins such as mabs []. It is important to make the right LC column choice for MS compatibility and improved separation of mabs and ADC. For guidance on using silica based columns with LC/MS for mab separations, refer to Agilent application notes: 99-9EN, 99-EN, 99-EN, and 99 9EN [-]. In this study, the polymeric-based PLRP-S column was used to analyze mabs and ADC at both the intact and fragment level. PLRP-S is robust and mechanically stable, and available in a range of pore and particle sizes suited for large biomolecule applications. Intact analysis Figure shows the LC/MS analysis of the intact mabs and ADC using a PLRP-S,. mm, µm,,å column. The column provided excellent TIC peak shapes with. minutes full width at half maximum (FWHM) mabs and. minutes FWHM ADC. The narrow TIC peak width was obtained using a standard RP mobile phase system (ACN + FA). Similar peak widths were observed for two mabs, demonstrating the suitability of the method for various mab samples. Narrow peak width was also demonstrated with the ADC sample, which is highly heterogeneous. The same method conditions and column were also tested with UV detection, and the results were satisfactory with identical retention time profiles (data not shown). 8 mab 8 mab 8 mab FWHM =.8 FWHM:. FWHM:. 7 8 9 7 8 9 7 8 9 7 7. GF/GF GF/GF D 8,.8 GF/GF or (GF).8. 7,. D,. 7,.,8.99. D D.,8.99.. GF/GF or (GF) D 8,8.. 9,. D. GF/GF,.99 8,.8.8 GF/GF GF/GF D. GF/GF. 7,8. 7,. 8,. 8,. D 7.8,99. G/GF.. 7,9.. D 8 7,9 8, 8, 8, 7, 7, 7, 7, 9,,,, Figure. Intact mab/adc LC/MS analysis on an Agilent PLRP-S,. mm, µm,,å column. Top: Total ion chromatogram; bottom: Deconvoluted spectrum. FWHM: full width at half maximum.

The raw mass spectra were converted to zero-charge mass spectra using Agilent MassHunter BioConfirm software. Figure shows the deconvoluted spectra. Five major glycoforms are seen in the mab deconvoluted spectrum, while four major glycoforms are evident in the mab spectrum. The deconvoluted mass spectra for ADC showed increasing payload trend in steps of one drug load with eight major drug conjugations (D to D8). Fragment analysis To analyze the generated fragments, the samples were subjected to chemical and enzymatic reactions. Figure shows the LC/MS separation of reduced, IdeS and papain digested mabs and ADC using a PLRP-S,. mm, µm,,å column. The fragment peaks (LC, HC, ScFc, F(ab ), Fc, * Fab, and ADC fragments with different drug conjugates species) are well separated on the PLRP-S column using the standard mobile phase system (ACN + FA). As expected, the two mab samples resulted in two major fragments post digestion. 9....8... mab mab ADC 9 8 HC.8 HC 9 LC - HC -. 8 LC. 7 LC...8... 7 8 9 7 8 9 7 8 9 9 9 9 ScFc ScFc......8... ScFc -. F(ab ).8. F(ab ) F(ab ) - 7 8 9 7 8 9 7 8 9 9 9 9. Fc -. * Fab Fc * Fab Fc. * Fab -......8.8.8....... 7 8 9.8.... 7 8 9.... 7 8 9 Figure. mab fragment LC/MS analysis on an Agilent PLRP-S,. mm, µm,,å column. Top: reduction; middle: IdeS digestion; bottom: papain digestion.

The separations between these major fragment peaks are sufficient to enable better MS sensitivity and accurate molecular weight determination (Figure ). Separation of the fragment species is very challenging with ADC samples, as conjugation at the various available lysine residues results in a high degree of heterogeneity. Figure shows the separation of glycosylated ADC fragments on the PLRP-S column. It is evident that different drug conjugated species are reasonably separated under the discussed LC/MS conditions, which demonstrates the separation performance of the PLRP-S column. Figure shows the representative deconvoluted spectra for mab and ADC fragments. Conclusion The Agilent PLRP-S column demonstrates superior separation performance for the analysis of mabs and ADC at both intact and fragment levels. The Agilent PLRP-S provided better chromatographic performance and high-quality MS response with formic acid-containing mobile phases. Analyses of mabs and ADC using Agilent PLRP-S columns coupled to an Agilent Accurate-Mass Q-TOF LC/MS has been demonstrated. mab ADC L 7,. GF,.8 H LC HC,9. LC 8 HC,7.79 GF H,77.7,8.9 GF L H,9.8,97.7,7. G L H,9.,8.7,.79,7.,,,,,,,,,,,,,,,,, Figure. Representative deconvoluted mass spectrum. Top: reduction; middle: IdeS digestion; bottom: papain digestion. GF 7,.8 97,.7 ScFc F(ab ) ScFc 8 F(ab ),. ScFc 8 99,9.8 GF ScFc,9.7 F(ab ),9.8 F(ab ) F(ab ),.7 G 98,.,.7 F(ab ) GF,87.9 97,8.,7.8,7. ScFc F(ab ),.7 7,.,8.,,,,8 97, 97, 97,7 97,9 98,,, 7, 98,,,, * Fab GF 7 Fc 7,. 8,.9 * Fab Fc,98.9 * Fab Fc,99.7 * Fab 9,7.7 Fc G GF,9.,8.,.7 * Fab GF,.9,7.8,7,9,,, 7, 7, 7,7 7,9,,,, 8, 9,,,

References. Beck, A.; Reichert, J. M. Antibody-drug conjugates. mabs, :, -7.. McCalley, D. V. Effect of buffer on peak shape of peptides in reversed-phase high performance liquid chromatography. Journal of Chromatography A, 8, 77 8.. Gudihal, R.; Suresh Babu C. V.; Tang, N. Analysis of Monoclonal Antibody(mAb) Using Agilent 9 InfinityLC System Coupled to Agilent Accurate- Mass Quadrupole Time-of-Flight (Q-TOF); Application note, Agilent Technologies, Inc. Publication number 99 EN,.. Suresh Babu, C. V. LC/MS of Intact TherapeuticMonoclonal Antibodies Using Agilent AdvanceBio RP-mAb. Application note, Agilent Technologies, Inc. Publication number 99 9EN,.. Gudihal, R.; Suresh Babu, C. V.; Tang, N.; Madhavi H. N.; Uma, M. Intact Protein Analysis using an Agilent Q-TOF Mass Spectrometer. Application note, Agilent Technologies, Inc. Publication number 99 EN,.. Martosella, J.; Duong, P.; Moyer, S. Rapid UHPLC Analysis of Reduced Monoclonal Antibodies using an Agilent ZORBAX Rapid Resolution High Definition (RRHD) SB-C8 Column. Application note, Agilent Technologies, Inc. Publication number 99-9EN,. For More Information These data represent typical results. For more information on our products and services, visit our Web site at www.agilent.com/chem. www.agilent.com/chem/advancebio For Research Use Only. Not for use in diagnostic procedures. This information is subject to change without notice. Agilent Technologies, Inc., Printed in the USA August, 99-7EN